



**Proteomics International**

LABORATORIES LTD

ASX release

27 January 2023

ASX code: PIQ

## Exercise of Options

Proteomics International Laboratories Ltd (Proteomics International; ASX: PIQ) is pleased to advise that the Company has today issued a total of 2,350,000 fully paid ordinary shares (Shares) upon the exercise of unquoted options raising \$1,725,000 before costs. The options comprised 2,200,000 corporate advisory options exercisable at \$0.75 per option expiring 28 January 2023 and 150,000 corporate advisory options exercisable at \$0.50 per option expiring 27 March 2023. The option exercise has resulted in long term shareholders increasing their positions in the company.

An Appendix 2A applying for quotation of the Shares has been lodged separately.

### Secondary Trading Notice Pursuant to Paragraph 708A(5)(e) of the Corporations Act 2001 ("Act")

The Act restricts the on-sale of securities issued without disclosure, unless the sale is exempt under section 708 or 708A of the Act. By giving this notice, a sale of the Shares noted above will fall within the exemption in section 708A(5) of the Act.

The Company hereby notifies ASX under paragraph 708A(5)(e) of the Act that:

- (a) the Company issued the Shares without disclosure to investors under Part 6D.2 of the Act;
- (b) as at the date of this Notice, the Company has complied with the provisions of Chapter 2M of the Act as they apply to the Company, and section 674 of the Act; and
- (c) as at the date of this Notice, there is no information:
  - i. that has been excluded from a continuous disclosure notice in accordance with the ASX Listing Rules; and
  - ii. that investors and their professional advisers would reasonably require for the purposes of making an informed assessment of:
    - a. the assets and liabilities, financial position and performance, profits and losses and prospects of the Company; or
    - b. the rights and liabilities attaching to the relevant Shares.

Authorised by the Board of Proteomics International Laboratories Ltd (ASX: PIQ).

ENDS

### For further information please contact:

Dr Richard Lipscombe  
Managing Director  
Proteomics International Laboratories Ltd  
T: +61 8 9389 1992  
E: [enquiries@proteomicsinternational.com](mailto:enquiries@proteomicsinternational.com)

Dirk van Dissel  
Investor Relations & Corporate Advisor  
Candour Advisory  
T: +61 408 326 367  
E: [dirk@candouradvisory.com.au](mailto:dirk@candouradvisory.com.au)

Kyle Moss  
Corporate Advisor  
Euroz Hartleys  
T: +61 8 9488 1400  
E: [kmoss@eurozhartleys.com](mailto:kmoss@eurozhartleys.com)

**Proteomics International Laboratories Ltd**

ABN 78 169 979 971

PO Box 3008, Broadway, Nedlands, WA 6009, Australia

T: +61 8 9389 1992 | E: [enquiries@proteomicsinternational.com](mailto:enquiries@proteomicsinternational.com) | W: [www.proteomicsinternational.com](http://www.proteomicsinternational.com)